Min Li

Prof. Min Li


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Hepatology International
Verified
Journal Article
Closed access
PDF file
MLMin Li
Min Li
TLTingting Lv
Tingting Lv
SWShanshan Wu
Shanshan Wu
WWWei Wei
Wei Wei
XWXiaohai Wu
Xiaohai Wu
JJJidong Jia
Jidong Jia

1 May 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
QTQiuju Tian
Qiuju Tian
RYRuiyuan Yang
Ruiyuan Yang
YWYan Wang
Yan Wang
JLJimin Liu
Jimin Liu
AWAileen Wee
Aileen Wee
JJJidong Jia
Jidong Jia

5 December 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
LSLijun Song
Lijun Song
HWHao Wang
Hao Wang
WYWenbo Yang
Wenbo Yang
MLMingan Li
Mingan Li
BXBoyan Xu
Boyan Xu
XLXu Liu
Xu Liu
Background: Neurovascular coupling (NVC) reflects the close connection between neural activity and cerebral blood flow (CBF) responses, providing new insights to explore the neuropathological mechanisms of various diseases. Non‐dialysis patients with chronic kidney disease (CKD) exhibit cognitive decline, but the underlying pathological mechanisms are unclear.Methods: The prospective study involved 53 patients with stage 1–3a CKD (CKD1–3a), 78 patients with stage 3b–5 CKD (CKD3b–5), and 52 healthy controls (HC). Our investigation involved voxel‐based assessments of both global and regional BOLD signal characteristics. Additionally, we explored the correlations between neuroimaging indices, Montreal Cognitive Assessment (MoCA) scores, and clinical laboratory findings.Results: Compared to HC, the CKD3b–5 and CKD1–3a groups exhibited lower ALLF and ReHo in the default mode network (DMN), higher CBF in bilateral hippocampus (HIP), higher susceptibility values in bilateral caudate nucleus (CAU) and putamen (PUT), and lower susceptibility values in bilateral HIP. At the global level, the coupling coefficients were lower in CKD1–3a and CKD3b–5 groups than in HC. At the ROI level, the CBF‐ALFF and CBF‐ReHo coupling in HIP and basal ganglia regions were lower in CKD3b–5 groups than in the CKD1–3a group. Most importantly, susceptibility‐ALFF in ANG.R may mediate the effects of phosphorus on cognitive decompensation in patients with CKD1‐3a.Conclusions: Non‐dialysis patients with CKD exhibit abnormal NCV, which is associated with the cognitive decline. Specifically, the susceptibility‐ALFF may serve as a valuable biomarker for early assessment of cognitive decline in CKD, offering insights into the pathogenesis of cognitive decline in CKD.

11 March 2024 in Hepatology Communications
Verified
Journal Article
Open access
XZXinyan Zhao
Xinyan Zhao
YWYan Wang
Yan Wang
RLRongtao Lai
Rongtao Lai
XWXiaojin Wang
Xiaojin Wang
YYYuecheng Yu
Yuecheng Yu
JJJidong Jia
Jidong Jia
Background & Aims: The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury. Methods: In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored. Results: A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926–0.964) vs. 0.867 (0.836–0.893), p=0.0016], conventional agents [0.923 (0.890–0.949) vs. 0.819 (0.775–0.858), p=0.0185], and herbs [0.972 (0.941–0.989) vs.0.911 (0.866–0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores. Conclusions: The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.

14 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMin Li
Min Li
YHYubei Huang
Yubei Huang
XDXin Du
Xin Du
SLShenshen Li
Shenshen Li
JJJiachao Ji
Jiachao Ji
YWYangfeng Wu
Yangfeng Wu
It is widely reported that long-term use of four preventive medications (antiplatelet agents, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, statin and beta-blockers) reduce the risk of subsequent acute coronary syndromes (ACS). It is unclear whether these four medications benefit patients who develop ACS despite its use. Logistic regression and propensity-score was applied among 14790 ACS patients to assess the association between prior use of four preventive medications and in-hospital outcomes including severity of disease at presentation (type of ACS, systolic blood pressure = 100 beats/min), complicating arrhythmia and major adverse cardiovascular events (MACEs, including all deaths, non-fatal myocardial infarction or re-infarction, and non-fatal stroke). Prior use of each of the four medications was significantly associated with less severity of disease (ORs ranged from 0.40 to 0.82, all P<0.05), less arrhythmia (ORs ranged from 0.45 to 0.64, all P<0.05), and reduced risk of MACEs (ORs ranged from 0.59 to 0.73, all P<0.05) during hospitalization. Multiple variable-adjusted ORs of MACEs were 0.77, 0.67, 0.48 and 0.59 respectively in patients with 1, 2, 3 and 4 medications in comparison with patients with none, and other clinical outcomes showed the same trend (P for trend < 0.05). Among ACS patients in our study, those with prior use of four preventive medications presented with less disease severity, developed less arrhythmia and had a lower risk of in-hospital MACEs. The value of taking these medications may beyond just preventing occurrence of the disease.

18 January 2024 in Journal of Medical Virology
Verified
Journal Article
Closed access
MLMin Li
Min Li
ZWZaihua Wei
Zaihua Wei
JSJianting Su
Jianting Su
XWXiaoning Wu
Xiaoning Wu
XXXueqin Xie
Xueqin Xie
YKYuanyuan Kong
Yuanyuan Kong